U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07643012) titled 'Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer' on May 27.
Brief Summary: To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Endometrial Cancer
Intervention:
RADIATION: MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)
Participants receive moderately hypofractionated MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) delivered via MR-linac to a total dose of 42 Gy in 15 fracti...